Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus CHOP-14 versus CHOP-14 alone in elderly CD20-positive non-Hodgkin lymphoma
NL-OMON28411Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2001
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 1 more (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Nov 2001; status: active, not recruiting.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON28411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28411.